Treatment Action Group Statement on Early Findings from HPTN 084
Statement / Press • 2020Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.
Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5
Statement / Press • 2019The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
A Lower Rifapentine Price Is Just a Start
PDF • 2019A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy
Letters • 2019October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they’re concerned that it doesn’t apply to all countries. Read/Download the comment
TAG Testimony to the FDA on New Drug Application for Pretomanid Tablets
Letters PDF • 2019TAG Testimony to the FDA on New Drug Application for Pretomanid Tablets TAG submitted testimony to the U.S. Food and Drug Administration (FDA) and the Antimicrobial Drugs Advisory Committee on New Drug Application (NDA) 212862 for pretomanid, proposed as part of a combination regimen with bedaquiline and linezolid (the Nix-TB regimen) in adults for the…
Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally
Statement / Press • 2019This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some of the biggest market-impact medicines purchased by the government, its flaws are so pervasive that—unless…
Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid
Statement / Press • 2019Treatment Action Group welcomes simpler, shorter treatment options for people with some forms of drug-resistant tuberculosis, while urging additional research and equitable access.
The High Cost of PrEP: Updates on Community and Health Department Efforts to Get Affordable TDF/FTC (Truvada) to Those Who Need It Most
Webinars • 2019This webinar took place on June 5 and gave an overview of the recent PrEP pricing advocacy that has taken place, and provided information on how webinar attendees can get more involved in ongoing community efforts to make PrEP affordable. We also looked at how health departments might benefit from a drastic reduction in the…
ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis
Statement / Press • 2019The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017
Advocates Must Press the CDC to Enforce its PrEP Patents in Order to End HIV as an Epidemic
Statement / Press • 2019TAG statement calling for advocates to stand with PrEP4All in demanding CDC enforce its PrEP patents.